<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1340">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727424</url>
  </required_header>
  <id_info>
    <org_study_id>TOGETHER_2</org_study_id>
    <nct_id>NCT04727424</nct_id>
  </id_info>
  <brief_title>Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms</brief_title>
  <official_title>A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine, Ivermectin and Metformin in Reducing Hospitalization of Patients With Mild COVID-19 and a High Risk of Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardresearch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardresearch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in&#xD;
      certain subgroups of patients. To date, no treatment has been shown to be effective in&#xD;
      patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a&#xD;
      potential anti-inflammatory role of Fluvoxamine, Metformin and Ivermectin in SARS-CoV-2&#xD;
      infections and observational studies have suggested a reduced complications in patients with&#xD;
      COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China&#xD;
      and a new subtype of coronavirus has been identified as the causative agent of this&#xD;
      condition. On February 11, 2000 the disease has been characterized as COVID-19 and on March&#xD;
      11 the World Health Organization (WHO) declared a state of worldwide pandemic. On January 25,&#xD;
      2021 there are 98,794,942 cases and 2,124,193 documented deaths (global case-fatality ratio&#xD;
      of 2.15%).&#xD;
&#xD;
      To date, no early treatment has been identified as effective in combating this disease which&#xD;
      has been identified as with high morbidity and mortality. Epidemiological data suggest that&#xD;
      despite development of vaccines we will have hundreds od thousands of cases in the next two&#xD;
      years.&#xD;
&#xD;
      Thus, we propose the repositioning of three drugs which experimentally have shown&#xD;
      anti-inflammatory activity against SARS-CoV2 and some clinical evidence derived from&#xD;
      observational studies on reducing complications if used early on the disease, before&#xD;
      inflammatory cascade is fully activated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly allocated to one of four treatment arms in a 1:1:1:1 ratio:&#xD;
Fluvoxamine&#xD;
Metformin&#xD;
Ivermectin&#xD;
Placebo. We will use a centralized random allocation schedule, generated by computer and implemented using an online remote access system. Randomization will be stratified by participating basic health unit.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigational medical product will be packaged in similar bottles by a third party who will keep the allocation confidential until the end of the study. The bottles will be sealed and identified as &quot;Research Product A, B, C, D and more letters if needed&quot; and with same colored labels. They will be randomly allocated among the participants.&#xD;
The research subjects, medical assistance, administrative and health staff will not have access to the contents of the bottles. Ivermectin bottles will have same placebo counterpart according to the weight.&#xD;
All planned Data and Safety Monitoring Board (DSMB) interim analysis will be blinded. If needed a unblinded statistician will be provided if DSMB decides to stop any arm. At the end of the study, or early termination as per DMSB interim analysis plan, the arms will then be identified.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of fluvoxamine, ivermectin and metformin in changing the need for emergency care AND observation for more than 06 hours due to the worsening of COVID-19;</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of emergency visits and observation unit stay &gt; 06 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of fluvoxamine, ivermectin and metformin in changing need for Hospitalization due to COVID-19 related complications, including lower respiratory tract infection (LRTI)</measure>
    <time_frame>28 days</time_frame>
    <description>Hospitalization due to COVID-19 progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in viral load on day 03 and 07 after randomization (first 600 enrolled participants)</measure>
    <time_frame>Day 3 and Day 7</time_frame>
    <description>Viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms)</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>time to &gt; 50% clinical symptoms changes (self reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Time to hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with respiratory symptoms since randomization</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Days with symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause hospitalizations</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>All cause hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COVID-19 related hospitalizations</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>COVID-19 hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Death</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Death all cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory death</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>REspiratory death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and Functioning after COVID-19 disease</measure>
    <time_frame>Day 14 and Day 28</time_frame>
    <description>Self evaluation of health functioning post COVID using Promis Global Health Score. Short term scale is a 10 item patient-reported questionnaire using response options as a 5-point and one 11 point rating scale. Higher scores means better global health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO ordinal scale for clinical improvement</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>An 8 item Ordinal Scale for clinical status on COVID-19. Higher numbers means worse clinical status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>randomization through day 28</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence of Study drug</measure>
    <time_frame>Randomization through day 10</time_frame>
    <description>Percentage of adherence on Study drug</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2724</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-Associated Coronavirus</condition>
  <arm_group>
    <arm_group_label>Fluvoxamine Maleate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluvoxamine 100 mg oral tablets: One tablet right after randomization followed by 100 mg twice a day for the following 09 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin HCL 750 mg extended release tablets: one tablet right after randomization followed by 750 mg twice a day for the following 09 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin 06 mg oral tablets or 5, 10 and 20 mg sublingual waffle:&#xD;
Tablets or waffles started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (talc)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablets: one tablet right after randomization followed by one tablet twice a day for the following 09 days;&#xD;
OR&#xD;
Placebo oral tablets or placebo sublingual waffles:&#xD;
Matching tablets or waffles started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine Maleate 100 MG [Luvox]</intervention_name>
    <description>One tablet every 12 hours since randomization through day 09.</description>
    <arm_group_label>Fluvoxamine Maleate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Extended Release Oral Tablet</intervention_name>
    <description>One 750 mg extended release tablet every 12 hours since randomization through day 09.</description>
    <arm_group_label>Metformin HCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin oral tablets or sublingual waffles</intervention_name>
    <description>Tablets or waffles will be started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day).</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Talc oral tablets:&#xD;
One tablet every randomization since randomization through day 09&#xD;
OR&#xD;
talc oral tablets or placebo sublingual waffles: Matching tablets or waffles started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day).</description>
    <arm_group_label>Placebo (talc)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 18 years old with the ability to provide free and informed consent&#xD;
&#xD;
          2. Acute Flu-Like symptoms &lt; 07 days.&#xD;
&#xD;
          3. All patient need to have at lease ONE enhancement factor:&#xD;
&#xD;
               1. Age &gt; 50 years;&#xD;
&#xD;
               2. Diabetes mellitus requiring oral medication or insulin&#xD;
&#xD;
               3. Systemic arterial hypertension requiring at least 01 oral medication for BP&#xD;
                  control;&#xD;
&#xD;
               4. Known cardiovascular diseases (heart failure, congenital heart disease, valvar&#xD;
                  heart valve disease, coronary artery disease, cardiomyopathies)&#xD;
&#xD;
               5. Symptomatic lung disease (emphysema, chronic bronchitis)&#xD;
&#xD;
               6. Symptomatic asthma patients requiring chronic use of agents for control of&#xD;
                  symptoms.&#xD;
&#xD;
               7. Smoking&#xD;
&#xD;
               8. Obesity, defined as BMI&gt; 30 kg / m2 body weight&#xD;
&#xD;
               9. Transplanted patients&#xD;
&#xD;
              10. Patient with stage IV chronic kidney disease or on dialysis.&#xD;
&#xD;
              11. Immunosuppressed patients / using corticosteroid therapy (equivalent to at least&#xD;
                  10 mg of prednisone per day) and / or immunosuppressive therapy)&#xD;
&#xD;
              12. Patients with a history of cancer in the last 05 years or undergoing treatment of&#xD;
                  a current cancer&#xD;
&#xD;
              13. Chronic renal disease KDIGO IV or End-Stage Renal Disease on chronic ambulatory&#xD;
                  renal replacement therapy&#xD;
&#xD;
          4. Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of the&#xD;
             screening or patient with a positive SARS-CoV2 diagnostic test within 07 days of the&#xD;
             onset of symptoms.&#xD;
&#xD;
          5. Willingness to use the proposed investigative treatment and follow the&#xD;
             protocol-related procedures foreseen in the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Negative SARS-CoV2 test.&#xD;
&#xD;
          2. Flu-like symptom onset 08 days or more.&#xD;
&#xD;
          3. Patients with COVID-19 being referred for hospitalization;&#xD;
&#xD;
          4. Patients with history of SARS-CoV-2 vaccine shot;&#xD;
&#xD;
          5. Patients with acute respiratory conditions due to other causes;&#xD;
&#xD;
          6. Dyspnea secondary to other acute and chronic respiratory causes or infections (eg:&#xD;
             Decompensated COPD, acute bronchitis, pneumonia, primary pulmonary arterial&#xD;
             hypertension)&#xD;
&#xD;
          7. Acute Flu-Like condition presenting with at least ONE of the criteria below:&#xD;
&#xD;
               1. Respiratory Rate&gt; 28 / min;&#xD;
&#xD;
               2. SaO2 &lt;90% or &lt;93% in nasal oxygen therapy at 10 l / min;&#xD;
&#xD;
               3. PaO2 / FIO2 &lt;300 mmHg&#xD;
&#xD;
          8. Patients using serotonin reception inhibitors (Donepezil, Sertraline)&#xD;
&#xD;
          9. Use of the following medications in the last 14 days:&#xD;
&#xD;
               1. Monoamine Oxide Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Selegiline,&#xD;
                  Isocarboxazide, moclobemide;&#xD;
&#xD;
               2. Use of iodinated contrasts during start of treatment through D14;&#xD;
&#xD;
               3. Use of antiretroviral agents&#xD;
&#xD;
         10. Patients with severe psychiatric disorders or major uncontrolled depression or&#xD;
             controlled with any of the prohibited drugs (see above);&#xD;
&#xD;
         11. Pregnant or breastfeeding patients;&#xD;
&#xD;
         12. History of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients&#xD;
             with ventricular fibrillation recovered) or Long QT Syndrome;&#xD;
&#xD;
         13. History of diabetic ketoacidosis or clinical condition that maintains persistent&#xD;
             acidosis&#xD;
&#xD;
         14. Surgical procedure or use of contrast designed to occur during treatment or up to 04&#xD;
             days after the last dose of the study medication;&#xD;
&#xD;
         15. Current daily and / or uncontrolled alcoholism;&#xD;
&#xD;
         16. History of seizures in the last month or uncontrolled medical condition;&#xD;
&#xD;
         17. Clinical history of Liver Cirrhosis or Child-Pugh C classification;&#xD;
&#xD;
         18. Patients with known severe degenerative neurological diseases and / or diseases&#xD;
             serious mental disorders;&#xD;
&#xD;
         19. Inability of the patient or representative to give consent or adhere to the procedures&#xD;
             proposed in the protocol;&#xD;
&#xD;
         20. Known hypersensitivity and / or intolerance to Fluvoxamine, Ivermectin or Metformin;&#xD;
&#xD;
         21. Inability to take oral or sublingual medications;&#xD;
&#xD;
         22. Inability to follow protocol-related procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gender will be assumed as patient self-reported</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilmar Reis, MD,PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Cardresearch - Cardiologia Assistencial e de Pesquisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward J Mills, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilmar Reis, MD, PhD</last_name>
    <phone>+553132416574</phone>
    <email>administrador@cardresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Santos, MD, PhD</last_name>
    <phone>+553132416574</phone>
    <email>duduaugusto1@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Ibirité</name>
      <address>
        <city>Ibirité</city>
        <state>MG</state>
        <zip>30240528</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Milagres, RN</last_name>
    </contact>
    <contact_backup>
      <last_name>Carla Silva, SC</last_name>
      <email>hsfapesq@cardresearch.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>City of Sete Lagoas</name>
      <address>
        <city>Sete Lagoas</city>
        <state>MG</state>
        <zip>35700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinicius Correa, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Castilho Vitor Quirino, SC</last_name>
      <email>vitor-quirino@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CARDRESEARCH - Cardiologia Assistencial e de Pesquisa</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150240</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabel Silva, SC</last_name>
      <phone>553132416574</phone>
      <email>coordpesq@cardresearch.org</email>
    </contact>
    <investigator>
      <last_name>Gilmar Reis, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Brumadinho</name>
      <address>
        <city>Brumadinho</city>
        <state>Minas Gerais</state>
        <zip>35.460-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Calegari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Calegari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Universitário FIPMOC</name>
      <address>
        <city>Montes Claros</city>
        <state>Minas Gerais</state>
        <zip>39.408-007</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Maria R Nogueira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Paula FG Alvarenga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Ouro Preto</name>
      <address>
        <city>Ouro Preto</city>
        <state>Minas Gerais</state>
        <zip>35400000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Savassi, MD, PhD</last_name>
      <email>leosavassi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonardo Savassi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Randomized study</keyword>
  <keyword>Fluvoxamine</keyword>
  <keyword>Ivermectin</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient tables and main data.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>As of protocol termination</ipd_time_frame>
    <ipd_access_criteria>Upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

